LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 86

Search options

  1. Article: [Merkel Cell Carcinoma].

    Sulkes, Aaron / Fenig, Eyal

    Harefuah

    2021  Volume 160, Issue 3, Page(s) 189

    MeSH term(s) Carcinoma, Merkel Cell ; Humans ; Skin Neoplasms
    Language Hebrew
    Publishing date 2021-03-22
    Publishing country Israel
    Document type Letter
    ZDB-ID 953872-0
    ISSN 0017-7768
    ISSN 0017-7768
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 291: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Comentarios de Aarón Sulkes al manuscrito de Uscanga.

    Sulkes, Aarón

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

    2005  Volume 57, Issue 1, Page(s) 100; author reply 101

    Title translation Aarón Sulkes' comments made to Uscanga's paper.
    MeSH term(s) Chemotherapy, Adjuvant ; Gastrointestinal Stromal Tumors/drug therapy ; Humans ; Terminology as Topic
    Language Spanish
    Publishing date 2005-01
    Publishing country Mexico
    Document type Comment ; Letter
    ZDB-ID 138348-6
    ISSN 0034-8376
    ISSN 0034-8376
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 288: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer.

    Mullin, Gil / Sternschuss, Michal / Landman, Yosef / Sulkes, Aaron / Brenner, Baruch

    World journal of gastrointestinal oncology

    2023  Volume 15, Issue 11, Page(s) 1913–1924

    Abstract: Background: In recent years survival of patients with metastatic colorectal cancer (mCRC), though still limited, has improved significantly; clearly, when the disease becomes refractory to standard regimens, additional treatment options are needed. ... ...

    Abstract Background: In recent years survival of patients with metastatic colorectal cancer (mCRC), though still limited, has improved significantly; clearly, when the disease becomes refractory to standard regimens, additional treatment options are needed. Studies have shown that mitomycin C (MMC), an antitumor antibiotic, and capecitabine, a precursor of 5-fluorouracil, may act synergistically in combination. The efficacy of MMC/capecitabine has been demonstrated in the first-line setting, but only a few small studies have tested it in the advanced-line setting, with contradictory results.
    Aim: To summarize our experience using MMC/capecitabine as an advanced line treatment for mCRC.
    Methods: A retrospective study was conducted at a tertiary medical center including all patients with histologically proven mCRC who were treated with MMC/capecitabine after at least two previous lines of standard chemotherapy in 2006-2020. Data on patient demographics and past medical history, laboratory, pathological, and radiological factors, and treatment and survival were collected from the files. Survival analyses were performed using the Kaplan-Meier method. The association of patient and tumor characteristics with treatment effectiveness and toxicity was evaluated with univariate and multivariate proportional hazard Cox regression analyses.
    Results: The cohort consisted of 119 patients of median age 64 years (range 37-85). Patients received a median of 2 MMC/capecitabine cycles (range 0.5-9.0). Thirty-four patients (28.6%) experienced grade ≥ 3 toxicity, including 2 (1.7%) with grade 4; there was no drug-related mortality. The objective response rate was 0.8%, and the disease control rate, 24.4%. Median progression-free survival (PFS) was 2.1 mo (range 0.2-20.3), and median overall survival, 4.8 mo (range 0.2-27.5). The 6-month overall survival rate was 44%; 8.7% of patients remained progression-free. Factors associated with longer PFS were lower gamma-glutamyl transferase level (
    Conclusion: MMC/capecitabine is an active, available, and relatively safe regimen for use beyond standard lines of therapy in mCRC. Several clinical and laboratory parameters can identify patients more likely to benefit.
    Language English
    Publishing date 2023-11-23
    Publishing country China
    Document type Journal Article
    ZDB-ID 2573696-6
    ISSN 1948-5204
    ISSN 1948-5204
    DOI 10.4251/wjgo.v15.i11.1913
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Docetaxel-induced Acute Myositis.

    Sulkes, Aaron / Reinhorn, Daniel / Cohen, Tzeela / Peysakhovich, Tatiana / Neiman, Victoria / Brenner, Baruch

    The Israel Medical Association journal : IMAJ

    2023  Volume 25, Issue 1, Page(s) 75–76

    MeSH term(s) Humans ; Docetaxel/adverse effects ; Myositis/chemically induced ; Myositis/diagnosis ; Acute Disease
    Chemical Substances Docetaxel (15H5577CQD)
    Language English
    Publishing date 2023-01-31
    Publishing country Israel
    Document type Case Reports ; Journal Article
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Comment to Moady et al. A Comparative Retrospective Study of Patients with Takotsubo Syndrome and Acute Coronary Syndrome.

    Sulkes, Aaron / Itzhaki Ben Zadok, Osnat / Neiman, Victoria / Brenner, Baruch

    The Israel Medical Association journal : IMAJ

    2021  Volume 23, Issue 6, Page(s) 395–396

    MeSH term(s) Acute Coronary Syndrome/diagnosis ; Acute Coronary Syndrome/epidemiology ; Coronary Angiography ; Humans ; Retrospective Studies ; Takotsubo Cardiomyopathy/diagnosis ; Takotsubo Cardiomyopathy/epidemiology
    Language English
    Publishing date 2021-06-21
    Publishing country Israel
    Document type Letter ; Comment
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Strong Synergic Growth Inhibition and Death Induction of Cancer Cells by

    Cohen, Zoya / Maimon, Yair / Samuels, Noah / Brand, Hadar / Sulkes, Aaron / Brenner, Baruch / Berger, Raanan

    Cancers

    2022  Volume 14, Issue 23

    Abstract: We present here a new, classification-based screening method for anti-cancer botanical combinations. Using this method, we discovered that the combination ... ...

    Abstract We present here a new, classification-based screening method for anti-cancer botanical combinations. Using this method, we discovered that the combination of
    Language English
    Publishing date 2022-11-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers14235833
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.

    Sulkes, Aaron

    The Israel Medical Association journal : IMAJ

    2010  Volume 12, Issue 10, Page(s) 628–632

    Abstract: The introduction of novel targeted therapies into the clinic in recent years has had a considerable impact on the management of several neoplastic diseases--such as gastrointestinal stromal tumors, hepatocellular carcinomas and renal cell carcinomas-- ... ...

    Abstract The introduction of novel targeted therapies into the clinic in recent years has had a considerable impact on the management of several neoplastic diseases--such as gastrointestinal stromal tumors, hepatocellular carcinomas and renal cell carcinomas--considered until recently refractory to systemic therapies. We describe here two such novel biological agents, sunitinib and sorafenib, as a paradigm of the successful clinical application of new concepts. Sunitinib and sorafenib are small molecule tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, C-Kit and others. Both agents are administered orally; sunitinib is tyically given in cycles for 4 consecutive weeks with 2 weeks off, while sorafenib is given continually. Side effects occur in most patients, similar for both agents; they may affect several systems and organs but are mostly mild and easily manageable, rarely requiring discontinuation of the drug. However, these toxicities mandate prompt attention and intervention. The most frequently observed effects are hypertension, nausea, anorexia, asthenia and cutaneous manifestations; cardiac abnormalities may include congestive failure. Sunitinib, and markedly less frequently sorafenib, may cause thyroid gland dysfunction, mainly hypothyroidism. Antitumor activity has been shown for renal cell carcinoma in pivotal trials, for sunitinib as first-line treatment and for sorafenib in previously treated patients as second-line. Sunitinib is now approved as second-line therapy for patients with GIST refractory to imatinib; sorafenib has resulted in a significant prolongation in median survival in patients with hepatocellular carcinoma. Ongoing clinical trials will further define the spectrum of these agents' antitumor activity, their role in combination with other drugs, as well as their optimal dose and schedule of administration.
    MeSH term(s) Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Benzenesulfonates/pharmacology ; Benzenesulfonates/therapeutic use ; Humans ; Indoles/pharmacology ; Indoles/therapeutic use ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/pharmacology ; Pyridines/therapeutic use ; Pyrroles/pharmacology ; Pyrroles/therapeutic use
    Chemical Substances Antineoplastic Agents ; Benzenesulfonates ; Indoles ; Phenylurea Compounds ; Protein Kinase Inhibitors ; Pyridines ; Pyrroles ; Niacinamide (25X51I8RD4) ; sorafenib (9ZOQ3TZI87) ; sunitinib (V99T50803M)
    Language English
    Publishing date 2010-10
    Publishing country Israel
    Document type Journal Article ; Review
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Comentario al artículo: Supervivencia después de prostatectomía radical en paciente con cáncer de próstata e invasión a vesícula seminal.

    Sulkes, Aaron

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

    2009  Volume 61, Issue 2, Page(s) 181; author reply 182

    Title translation Comments to the manuscript: Survival after radical prostatectomy in patient with prostate cancer and seminal vesicle invasion.
    MeSH term(s) Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Humans ; Magnetic Resonance Imaging ; Male ; Neoplasm Invasiveness ; Prostatectomy ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/surgery ; Seminal Vesicles/pathology ; Seminal Vesicles/surgery
    Language Spanish
    Publishing date 2009-03
    Publishing country Mexico
    Document type Comment ; Letter
    ZDB-ID 138348-6
    ISSN 0034-8376
    ISSN 0034-8376
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 288: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: The emerging role of the new aromatase inhibitors in the treatment of breast cancer.

    Sulkes, Aaron

    The Israel Medical Association journal : IMAJ

    2005  Volume 7, Issue 4, Page(s) 257–261

    Abstract: The clinical development of aromatase inhibitors in recent years represents a significant addition to our armamentarium for the treatment of postmenopausal patients with hormone receptor-positive breast cancer--both for metastatic disease and in the ... ...

    Abstract The clinical development of aromatase inhibitors in recent years represents a significant addition to our armamentarium for the treatment of postmenopausal patients with hormone receptor-positive breast cancer--both for metastatic disease and in the adjuvant setting. In patients with metastatic disease, third-generation aromatase inhibitors have shown significantly superior efficacy over tamoxifen as first-line hormone therapy. In the adjuvant setting, preliminary results with the use of aromatase inhibitors in ongoing large clinical trials indicate significant gains in disease-free survival rates and in the occurrence of contralateral breast cancer, either alone for 5 years or sequentially after tamoxifen for 2-3 or 5 years. While tamoxifen monotherapy continues to be standard adjuvant therapy for patients with low risk primary breast cancer, postmenopausal patients with higher risk hormone-positive primary breast cancer should also be offered an aromatase inhibitor. Aromatase inhibitors are also prescribed for patients with contraindications to tamoxifen. The optimal sequence and duration of aromatase inhibitor adjuvant therapy as well as its long-term impact on overall survival remain to be established. In general, aromatase inhibitors have a good toxicity profile. Long-term effects such as the risk of osteoporosis need to be better defined.
    MeSH term(s) Age Factors ; Aromatase Inhibitors/administration & dosage ; Aromatase Inhibitors/chemistry ; Aromatase Inhibitors/therapeutic use ; Breast Neoplasms/drug therapy ; Chemotherapy, Adjuvant ; Drug Therapy, Combination ; Female ; Humans ; Postmenopause ; Treatment Outcome
    Chemical Substances Aromatase Inhibitors
    Language English
    Publishing date 2005-04
    Publishing country Israel
    Document type Journal Article ; Review
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.

    Sulkes, Aaron

    The Israel Medical Association journal : IMAJ

    2004  Volume 6, Issue 7, Page(s) 415–419

    MeSH term(s) Antineoplastic Agents/therapeutic use ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Carcinoma/drug therapy ; Chemotherapy, Adjuvant/methods ; Humans ; Organoplatinum Compounds/therapeutic use ; Paclitaxel/therapeutic use ; Pyrimidines/therapeutic use ; Stomach Neoplasms/drug therapy ; Taxoids/therapeutic use
    Chemical Substances Antineoplastic Agents ; Organoplatinum Compounds ; Pyrimidines ; Taxoids ; oxaliplatin (04ZR38536J) ; docetaxel (15H5577CQD) ; irinotecan (7673326042) ; Paclitaxel (P88XT4IS4D) ; Camptothecin (XT3Z54Z28A)
    Language English
    Publishing date 2004-07
    Publishing country Israel
    Document type Journal Article ; Review
    ZDB-ID 2008291-5
    ISSN 1565-1088 ; 0021-2180
    ISSN 1565-1088 ; 0021-2180
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top